Attenuation imaging for hepatic steatosis in chronic hepatitis B vs metabolic dysfunction-associated steatotic liver disease

doi:10.3748/wjg.v31.i11.102795

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 31, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (643)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-6) series, Tables (1-4) series.

Item

Count

PDF

HTML

390

Figures (1-6)

Tables (1-4)

Sum=565

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=44

Mar 21, 2025 (publication date) through Apr 3, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Gastroenterol. Mar 21, 2025; 31(11): 102795
Published online Mar 21, 2025. doi: 10.3748/wjg.v31.i11.102795

Table 1 Patient characteristics, n (%)

Characteristic	Total (n = 249)	CHB group (n = 78)	MASLD group (n = 171)	P value
Male	90 (36.14)	51 (65.38)	39 (22.81)	< 0.001^a
Age (years)	33 (28-39)	40 (33-47)	31 (26-35)	< 0.001^a
BMI (kg/m²)	33.71 (26.75-38.03)	23.48 (21.65-25.69)	36.33 (33.27-40.81)	< 0.001^a
Fasting glucose (mmol/L)	5.50 (5.10-6.40)	5.65 (5.20-6.27)	5.50 (5.10-6.40)	0.457
ALT (U/L)	41 (25-73)	37 (28-79)	43 (22-70)	0.325
AST (U/L)	26 (19-41)	27 (17-43)	29 (22-48)	0.101
ALP (U/L)	79 (67-95)	82 (69-106)	76 (65-93)	0.055
GGT (U/L)	35 (23-61)	31 (19-63)	35 (26-59)	0.199
TG (mmol/L)	1.53 (1.07-2.10)	1.47 (0.98-2.25)	1.55 (1.08-2.04)	0.788
HDL-C (mmol/L)	1.08 (0.93-1.30)	1.05 (0.89-1.26)	1.14 (0.97-1.52)	0.016^a
Steatosis grade				< 0.001^a
S0	62 (24.90)	45 (57.69)	17 (9.94)
S1	84 (33.73)	16 (20.51)	68 (39.77)
S2	79 (31.73)	15 (19.23)	64 (37.43)
S3	24 (9.64)	2 (2.56)	22 (12.87)
Fibrosis stage				< 0.001^a
F0	31 (12.45)	19 (24.36)	12 (7.02)
F1	71 (28.51)	29 (37.18)	42 (24.56)
F2	96 (38.55)	14 (17.95)	82 (47.95)
F3	46 (18.47)	11 (14.10)	35 (20.47)
F4	5 (2.01)	5 (6.41)	0 (0.00)

^aP < 0.05.

CHB: Chronic hepatitis B; MASLD: Metabolic dysfunction-associated steatotic liver disease; BMI: Body mass index; ALT: Alanine aminotransferase; AST: Aspartate transaminase; ALP: Alkaline phosphatase; GGT: Gamma-glutamyl transpeptidase; TG: Triglycerides; HDL-C: High density lipoprotein cholesterol.

Citation: Li XQ, Cheng GW, Akiyama I, Huang XJ, Liang J, Xue LY, Cheng Y, Kudo M, Ding H. Attenuation imaging for hepatic steatosis in chronic hepatitis B vs metabolic dysfunction-associated steatotic liver disease. World J Gastroenterol 2025; 31(11): 102795
URL: https://www.wjgnet.com/1007-9327/full/v31/i11/102795.htm
DOI: https://dx.doi.org/10.3748/wjg.v31.i11.102795